NVIC Articles

Uncategorized

Latest articles

Browse Articles

Placeholder image
Page

Menstrual cycle changes have been reported following mRNA COVID-19 vaccines. These included reports such as heavy menstrual periods, menstruation following menopause, and breakthrough periods in women using birth control pills....

Placeholder image
Page

There is little safety data available on the use of COVID-19 vaccines or mRNA vaccines in pregnant women and only limited data available from animal development and reproductive toxicity studies....

Placeholder image
Page

Early COVID-19 vaccine clinical trials nearly exclusively enrolled healthy adults between the ages of 18 and 55 years. Few studies involve persons over the age of 65, or those with...

Placeholder image
Page

Young males, especially those under the age of 40 years, are at a significant risk of myocarditis and pericarditis following COVID-19 mRNA vaccination.  In particular, males between 12 and 17...

Placeholder image
Page

On Mar. 10, 2020, the Secretary of Health and Human Services (HHS) invoked the 2005 Public Readiness and Emergency Preparedness (PREP) Act, after declaring that the COVID-19 pandemic was a...

Placeholder image
Page

As of the December 27, 2024 data release, vaccine adverse events submitted to VAERS associated with the Novavax COVID-19 vaccine totaled 706 with 95 noted as serious. Included in these...

Placeholder image
Page

According to the Fact Sheet for Health Care Providers administering Novavax COVID-19 vaccine, the most common side effects reported following vaccination were injection site pain and tenderness, malaise/fatigue, muscle pain,...

Placeholder image
Page

Novavax COVID-19 Vaccine Clinical Trial DataMaryland-based Novavax Inc, a biotechnology company which, prior to its COVID-19 vaccine, had never successfully delivered a product to market,  developed an experimental vaccine using...

Placeholder image
Page

As of the December 27, 2024 data release, vaccine adverse events submitted to VAERS associated with the Johnson & Johnson/Janssen COVID-19 vaccine totaled 99,696, with 17,806 noted as serious. Included...

Placeholder image
Page

In January 2022, the Pharmacovigilance and Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) reported that a reasonable association existed between the Janssen/Johnson & Johnson and AstraZeneca, an...

Topics
Select disease / vaccine